TD Cowen Sticks to Its Buy Rating for Iovance Biotherapeutics (IOVA)
In a report released today, Tyler Van Buren from TD Cowen maintained a Buy rating on Iovance Biotherapeutics (IOVA – Research Report).
Business Insider1h
Oppenheimer Sticks to Its Buy Rating for CyberArk Software (CYBR)
In a report released today, JMP Securities also reiterated a Buy rating on the stock with a $360.00 price target. CYBR market cap is currently $13.11B and has a P/E ratio of -869.75. TipRanks tracks ...